Position in LFCR
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$1,579,140
-$2,036,420 QoQ
Shares Held
424,500
-4.0% QoQ
Ownership
1.13%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
12 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LFCR Over Time
Shares Held
Position Value (USD)
Derivatives in LFCR
reported options exposure · as of Jun 30, 2023CallValue
$29,010
CallShares
3,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026DCF Advisers, LLC holds $13,278,325 across 3 Drug Manufacturers - Specialty & Generic names. LFCR ranks #3 (11.9% of the industry book) .
All Filings in LFCR
Export CSV
13 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,579,140 | 424,500 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $3,615,560 | 442,000 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $3,326,720 | 452,000 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $3,759,454 | 462,987 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $3,400,320 | 483,000 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $4,012,118 | 539,989 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $1,422,196 | 288,478 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $1,491,208 | 290,684 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $1,511,672 | 284,684 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $1,607,443 | 259,684 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $911,692 | 120,754 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $29,010 | 3,000 | Call | Sole | 2023-08-09 | |
| 2023-06-30 | $846,125 | 87,500 | Shares | Sole | 2023-08-09 | |
| No filing history on record for this holder in this stock. | ||||||